Pre-made Lebrikizumab benchmark antibody ( Whole mAb, anti-IL13 therapeutic antibody, Anti-IL-13/P600 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Lebrikizumab biosimilar, Whole mAb, Anti-IL13 Antibody: Anti-IL-13/P600 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lebrikizumab (INN) is a humanized monoclonal antibody and an experimental immunosuppressive drug for the treatment of asthma that cannot be adequately controlled with inhalable glucocorticoids. The drug was created by Tanox under the name TNX-650, and a phase I clinical trial for refractory Hodgkin's lymphoma had been performed when Genentech acquired Tanox in 2007. It has successfully completed a Phase II clinical trial for the treatment of asthma.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-299-1mg	1mg	3090
GMP-Bios-ab-299-10mg	10mg	Inquiry
GMP-Bios-ab-299-100mg	100mg	Inquiry
GMP-Bios-ab-299-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Lebrikizumab biosimilar, Whole mAb, Anti-IL13 Antibody: Anti-IL-13/P600 therapeutic antibody
INN Name	Lebrikizumab
Target	IL13
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Active
100% SI Structure	4i77:HL
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2009
Year Recommended	2010
Companies	Chugai Pharmaceutical;Comprehensive Clinical Research Network;Dermira;Genentech;Roche;Tanox
Conditions Approved	na
Conditions Active	Atopic dermatitis
Conditions Discontinued	Asthma;Chronic obstructive pulmonary disease;Hodgkin's disease;Idiopathic pulmonary fibrosis
Development Tech	na